Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer

BACKGROUND: In Her2-positive advanced breast cancer, the upfront use of trastuzumab is well established. Upon progression on first-line therapy, patients may be switched to lapatinib. Others however remain candidates for continued antibody treatment (treatment beyond progression). Here, we aimed to...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Bartsch, Rupert, De Vries, Catharina, Pluschnig, Ursula, Dubsky, Peter, Bago-Horvath, Zsuzsanna, Gampenrieder, Simon P, Rudas, Margaretha, Mader, Robert M, Rottenfusser, Andrea, Wiltschke, Christoph, Gnant, Michael, Zielinski, Christoph C, Steger, Guenther G
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2009
Konular:
Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC2770076/
https://ncbi.nlm.nih.gov/pubmed/19835621
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-9-367
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller